Showing results (211-220 of 260) with videos related to

Sort By:
Pageof 26
Oncology Reports|May 25, 2011
Prognostic-significance of multifocality in primary breast-cancerA Morabito, F Perrone, R Lauria, et al.
The New England Journal of Medicine|November 3, 1983
Prognostic value of exercise EKG testing in asymptomatic normotensive subjects. A prospective matched studyE Giagnoni, M B Secchi, S C Wu, et al.
Clinical and Experimental Immunology|May 5, 1998
Anti-mitochondrial M5 type antibody represents one of the serological markers for anti-phospholipid syndrome distinct from anti-cardiolipin and anti-beta2-glycoprotein I antibodiesL La Rosa, G Covini, C Galperin, et al.
Oncology Reports|May 21, 2011
Mitoxantrone, Etoposide and bleomycin (meb) chemotherapy in non-hodgkins-lymphoma patients non-elegible for standard cyclophosphamide, Doxorubicin, vincristine and prednisone (chop) combinationP Tagliaferri, E Matano, A Rea, et al.
Cancer Investigation|May 7, 2013
Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot studyP Queirolo, A Morabito, S Laurent, et al.
The Review of Scientific Instruments|August 1, 2016
Absolute dosimetric characterization of Gafchromic EBT3 and HDv2 films using commercial flat-bed scanners and evaluation of the scanner response function variabilityS N Chen, M Gauthier, M Bazalova-Carter, et al.
Il Giornale Di Chirurgia|November 1, 1996
[An update on parathyroid surgery]P Campi, R Cristofani, M F Burattini, et al.
Diabetes & Metabolism|June 30, 2004
Flexible treatment of gestational diabetes modulated on ultrasound evaluation of intrauterine growth: a controlled randomized clinical trialM Bonomo, I Cetin, M P Pisoni, et al.
The Cancer Journal From Scientific American|April 13, 1999
Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapyG Gasparini, M Toi, R Miceli, et al.
Oncology|October 17, 2002
Doxorubicin-docetaxel sequential schedule: results of front-line treatment in advanced breast cancerS Palmeri, V Leonardi, M Tamburo De Bella, et al.
Pageof 26